Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia’s current thinking with respect to future
Slide 3: Cantargia current owners and financial highlights
Cantargia Current owners (April 30, 2019) • Specialized in antibody therapy/immunology/oncology Sunstone 8.2% • Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020 Alecta 6.6% • Platform around IL1RAP, lead candidate for autoimmunity and
Slide 4: Cantargia – opportunity to save lives and create value
Cantargia – opportunity to save lifes and create value • Potentially more effective treatment against novel target in clinically validated pathway • Right team and clear plan to position our projects and maximize value • First in class platform technology against novel target 4
Slide 5: Lead project CAN04 in the highest growth segment – Oncology antibodies
Lead project CAN04 in the highest growth segment– Oncology antibodies Sales cancer therapeutic antibodies 2018 (2017) Rituxan/MabThera CHF 5.19bn (5.83bn) Avastin CHF 6.85bn (6.69bn) Herceptin CHF 6.98bn (7.01bn) Immuno-oncology driving market growth 2018 (2017) Opdivo $6.74bn ($4.95bn) Keytruda $7.
Slide 6: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial Phase I/IIa trial - NSCLC and pancreatic cancer • Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo • 22 patients (NSCLC, pancreatic cancer, colon cancer) • Good safety up to 10 mg/kg • Significant effect on r
Slide 7: Results from a First-in-man, Open label, Safety and tolerability Trial of CAN04
Results from a First-in-man, Open label, Safety and tolerability Trial of CAN04 (Nidanilimab), a Fully Humanized Monoclonal Antibody against the Novel Antitumor Target, IL1RAP, in Patients with Solid Tumor Malignancies • Oral presentation at ASCO (Developmental Immunotherapy and Tumor Immunobiology)
Slide 8: Biomarkers (serum)
Biomarkers (serum): (taken pre-dose at first and third dose) • Decrease in IL-6 in 17/21 subjects (median -18.4%, p=0.04) • Trend in CRP decrease in 13/17 subjects (median -21.6%, p=0.08) • Decreased levels of IL-6 and CRP consistent with the CAN04 MoA – supporting target engagement Decrease in biom
Slide 9: Clinical efficacy data
Clinical efficacy data • Twenty-one (21) patients had available pre- and post-treatment assessment by imaging and the following proportion of patients had stable disease (SD) by irRC as best overall response at 2 months : • One patient with NSCLC had PFS for 7 months (4 prior lines of therapy, inclu
Slide 10: CANFOUR – Phase IIa
CANFOUR – Phase IIa Phase IIa: (appr 20 centers) • FPI Jan 2019 • Monotherapy • Combination with chemotherapy • NSCLC cisplatin/gemcitabine • Pancreatic cancer gemcitabine/nab- paclitaxel • Tumor biopsies pre- and during treatment • Extensive biomarker analysis Preclinical data in NSCLC PDX model sh
Slide 11: Significant value inflection points ahead of CANFOUR results
Significant value inflection points ahead of CANFOUR results 2019 • ASCO - phase I data • US regulatory and clinical strategy • Clinical progress and initial phase IIa results • Preclinical progress (immuno-oncology effects, combinations etc) • CANxx progress • US clinical trial 2020 • Phase IIa res
Slide 12: Cantargia current owners and financial highlights
Cantargia Current owners (April 30, 2019) • Specialized in antibody therapy/immunology/oncology Sunstone 8.2% • Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020 Alecta 6.6% • Platform around IL1RAP, lead candidate for autoimmunity and